Southern Company Equity Method Investments decreased by 4.6% to $1.38B in Q3 2023 compared to the prior quarter. Year-over-year, this metric grew by 6.5%, from $1.29B to $1.38B. Over 2 years (FY 2020 to FY 2022), Equity Method Investments shows relatively stable performance with a 2.9% CAGR.
An increase indicates strategic expansion through partnerships or joint ventures, while a decrease may signal divestments or impairment.
These are investments in entities where the company exercises significant influence but does not have full control. The...
Varies significantly based on corporate strategy; common in healthcare companies that partner with biotech startups or specialized diagnostic firms.
equity_method_investments| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q3 '23 | |
|---|---|---|---|---|---|---|---|---|
| Value | $1.29B | $1.28B | $1.28B | $1.29B | $1.31B | $1.29B | $1.44B | $1.38B |
| QoQ Change | — | -0.7% | +0.3% | +0.9% | +0.9% | -1.0% | +11.7% | -4.6% |
| YoY Change | — | — | — | — | +1.4% | +1.1% | +12.6% | +6.5% |